{"id":588446,"date":"2026-04-30T00:00:00","date_gmt":"2026-04-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcg0173-biopharma-multiple-system-atrophy-epidemiology-epidemiology-multiple-system-atrophy-mature-markets\/"},"modified":"2026-04-30T00:00:00","modified_gmt":"2026-04-30T00:00:00","slug":"epidcg0173-biopharma-multiple-system-atrophy-epidemiology-epidemiology-multiple-system-atrophy-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcg0173-biopharma-multiple-system-atrophy-epidemiology-epidemiology-multiple-system-atrophy-mature-markets\/","title":{"rendered":"Multiple System Atrophy &#8211; Epidemiology &#8211; Epidemiology &#8211; Multiple system atrophy &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of multiple system atrophy (<abbr title=\"multiple system atrophy\">MSA<\/abbr>) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of <abbr title=\"multiple system atrophy\">MSA<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Patient populations are forecast over a period of 20 years, and the major mature pharmaceutical markets are covered in this report.<\/p>\n<p>Clarivate Epidemiology&#8217;s <abbr title=\"multiple system atrophy\">MSA<\/abbr> forecast will answer the following question:<\/p>\n<ul class=\"round-bullets\">\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"multiple system atrophy\">MSA<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <abbr title=\"Microsoft\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 3 <abbr title=\"multiple system atrophy\">MSA<\/abbr> patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed <abbr title=\"multiple system atrophy\">MSA<\/abbr> prevalent cases<\/li>\n<li>Diagnosed <abbr title=\"multiple system atrophy\">MSA<\/abbr> incident cases<\/li>\n<li>Diagnosed <abbr title=\"multiple system atrophy\">MSA<\/abbr> prevalent cases by UMSARS-IV disability stage<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-588446","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-neurology","biopharma-product-epidemiology","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/588446","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=588446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}